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ABSTRACT
A ZINDO/1 quantum-chemical structure-affinity relationship study with the KPG model is presented for the in vitro interaction of a group of classical, indole-
derived and aminoalkylindole-derived cannabinoids with CB
1
 and CB
2
 receptors. From this work the following conclusions are obtained. CB
1
  and CB
2
 CB
2 
receptor 
affinities are regulated by different mechanisms involving orbital and charge control. Nevertheless  CB
1 
and CB
2
 classical ligands share three common features: a 
hydrogen bond to a lysine (for CB
1
) or serine (for CB
2
), a fully aromatic ring and a branched carbon side chain. In the case of indole-derived and aminoalkylindole-
derived cannabinoids orientation and alignment rules have been defined as a basis for the comparison of noncongeneric molecules. In this way it was possible 
to associate the location of molecular fragments of these systems with known molecular systems such as classical cannabinoids. For aminoalkylindoles we have 
proposed the locus with which they bind to a second receptor site that is available to WIN-55212-2 but not to classical cannabinoids. On the basis of our results 
we propose a new molecule that should help to discriminate between the above two receptor sites.
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INTRODUCTION
Marijuana is a mixture of leaves, stems, and flowering tops of the Indian 
hemp plant Cannabis sativa (the genus Cannabis belongs to the family 
Moraceae). Marijuana has been used as a folk medicine for rheumatism, 
gout, malaria, and oddly enough, absent-mindedness, and for its psychoactive 
properties. The stems are an important source of hemp fiber and the seeds 
are a good source of edible oil. Long known in Central Asia and China, it 
was described in a Chinese medical compendium traditionally considered to 
date from 2737 B.C. Its use spread from China to India and then to North 
Africa and reached Europe at least as early as A.D. 500. The Muslims used it 
recreationally because alcohol consumption was banned by the Koran. It was 
the Muslims who introduced hashish – the resin of the plant -, whose popularity 
spread quickly throughout 12th century Persia and North Africa. In 1545 the 
Spanish brought hemp to the New World. About 1900 it started to be used 
as a pleasure-inducing drug in the West1. It was reported also that marijuana 
was sometimes used in folk medicine for treating gonorrhea in Sikkim, India2. 
Marijuana’s active components are potentially effective in treating pain, 
nausea, particularly related to cancer chemotherapy, anorexia in AIDS patients, 
and other conditions such as glaucoma.
The smoke produced by combustion of marijuana contains, among 
other chemicals, at least sixty-one different cannabinoids. One of these ∆9, -
tetrahydrocannabinol (∆9-THC, 8 in Figure 1) produces most of the classical 
pharmacological effects of smoked marijuana: changes in mood, perception 
and motivation. The typical marijuana smoker experiences a high lasting about 
2 hours with impairment of cognitive functions, perception, reaction time, 
learning, and memory.
Up to date two cannabinoid receptors have been described. They belong to 
the superfamily of G-protein-coupled membrane receptors. In humans, the CB
1
 
receptor is present primarily in the central nervous system and some peripheral 
neurons; it is particularly prevalent in the basal ganglia, hippocampus, 
cerebellum, and cerebral cortex3,4. The CB
2
 receptor is principally found 
in  the spleen, tonsils, bone marrow and peripheral blood leukocytes5,6. The 
search for an endogenous ligand led to the discovery of N-(2-hydroxyeth
yl)arachidonylamide (anandamide) which binds to the CB
1 
receptor with an 
affinity similar to that of ∆9-THC7,8. The discovery of anandamide and other 
N-acylethanolamines in chocolate elicited a controversy about the possibility 
that the purported rewarding properties of cocoa reflect the presence of this 
kind of compounds9-12.
There are several very different chemical structures that bind to cannabinoid 
receptors. This fact represents a challenge for the quantum chemist. To gain a 
deeper physical insight regarding the nature of the interaction of cannabinoids 
with their receptors, we present here the results of a formal in vitro structure-
affinity relationship study carried out for a variety of  CB
1 
and  CB
2 
ligands. 
Figure 1. Structure of the classical cannabinoids.
MATERIALS AND METHODS
As the method has been widely and thoroughly discussed in this Journal 
and elsewhere13-18, we shall present a very general sketch. Starting from the 
statistical-mechanical definition of the equilibrium constant, and using a set 
of physically-based approximations, we may derive the following equation 
containing only drug-related terms:
                     
 (1)
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where a, b, c, d and e are constants, D refers to the drug molecule, σ is the 
symmetry number, M the drug's molecular mass, is the product of the three 
moments of inertia about the three principal axes of rotation, and  is here the 
cannabinoid-receptor interaction energy. In our previous studies it has been 
shown that in the case of orbital contributions, the first, second and third 
occupied (HOMO, NHOMO and SHOMO respectively) and virtual (LUMO, 
NLUMO and SLUMO) molecular orbitals (MO) are involved.
The moment of inertia term deserves a comment. We proposed that this 
term could be expressed in a first approximation as18,19:
                                                          
 
(2) 
                                       
where the summation over t is over the different substituents of the 
molecule, mi,t is the mass of the i-th atom belonging to the r-th substituent,R
i,t
 
being its distance to the atom to which the substituent is attached. We must 
note here that this approximation enables us to transform a molecular property 
into a sum of local properties. We have called the right side of Eq. (2) the 
substituent’s orientational effect19. We have interpreted it (because it originates 
from the rotational partition function) as giving an account of the relative ease 
with which the correct drug-receptor alignment for the interaction occurs
When employed within a CNDO/2 level of parametrization, this approach 
produced excellent QSAR results for very different biologically active 
molecules14,15,18,20-22.
The following molecular systems and properties were selected:
a. Classical cannabinoid derivatives (Figure 1):  CB
1 
binding to rat 
synaptosomal membranes, CB
1 
binding to African green monkey kidney 
cells transfected with the cDNA of rat CB
1 
receptor, and CB
2 
 binding to 
COS-7 cells transfected with the cDNA of human CB
2 
receptors.
b. Indole-derived cannabinoids (Figure 2): CB
1  
binding to rat brain  P
2
 
membranes, and,
c. Aminoalkylindole-derived cannabinoids (Figure 3): Inhibition of [3 H]-
WIN-55212-2 binding to rat cerebellar membranes.
The values for the experimental properties were taken from the literature23-
25.
Figure 3. Structure of aminoethylindole-derived cannabinoids.
The molecules were studied in their neutral state. All the calculations were 
carried out by using the Hyperchem package26. Full geometry optimization was 
carried out using the AM1 semiempirical methodology27. The method selected 
for calculating the wave function was Zerner’s ZINDO/128,29. This choice 
is justified because after AM1 geometry optimization ZINDO/1 is the only 
method producing positive nucleophilic superdelocalizabilities as required by 
the model30. As expected, ZINDO/1 gave good results when applied to the 
interaction of a group of 3-substituted morphinans with mu, delta and kappa 
opioid receptors31, and for the CB
1
- and CB
2
-mediated inhibition of adenylyl 
cyclase by a group of classical cannabinoid derivatives32.
It must be noted that the equations for binding affinity were developed 
from the formal statistical-mechanical definition of the affinity constant. This 
leads to a system of simultaneous equations that must have a solution if the 
experimental results are correctly measured and the numerical values of the 
reactivity indices are calculated with a suitable quantum-chemical method.. 
To solve this system we must have the same number of experimental results 
and variables. The problem is that the number of molecules is generally less 
than the number of unknown quantities. For this reason statistical analysis 
is employed, not to see if there is a solution, but to find the best one. The 
statistical fitting of Eq. 1 was performed by means of a stepwise regression 
technique with the receptor affinities as the dependent variables and the static 
reactivity indices of the atoms belonging to a common skeleton as independent 
variables. The common skeleton for classical cannabinoids is shown in Fig. 
4. To these variables we added the orientational effect of the substituents 
placed at positions 6, 10 and 12. For indole-derived cannabinoids the common 
skeleton is shown in Fig. 5. We added here the orientational effect of the N-
substituents. For aminoalkylindole-derived cannabinoids the common skeleton 
is displayed in Fig. 6. We added the orientational effects of the ortho-, meta-, 
and para-substituents.
Figure 2. Structure of indole-derived cannabinoids.
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Figure 4. Common skeleton numbering for classical cannabinoids.
Figure 5. Common skeleton numbering for indole-derived cannabinoids.
RESULTS
For  CB
1 
 binding of classical cannabinoids to rat synaptosomal membranes 
the best equation obtained is:
       
     (3)
with R=0.98 and SD=0.31. The analysis of variance of Eq. 3 gives 
F(6,6)=25.76 (p<0.001), showing that this equation is statistically significant. 
Here, Q
5
  is the net charge of atom 5, Q
9
 is the net charge of atom 9,
is the orbital nucleophilic superdelocalizability of the LUMO at atom 9, O
3
 
is the orientational effect of the substituent attached to atom 12, and O
3
 is 
the same effect for the substituent attached to atom 10 (see Fig. 4 CB
1
). The 
predicted log K
i
 values are shown in Table 1.
Table 1. Experimental and calculated CB
1
 receptor affinities of classical 
cannabinoids to rat synaptosomal membranes.
Moleculea Experimental log Kb (nM) Calculated log Kc (nM)
1 2.59 2.23
2 0.52 0.38
3 2.28 2.16
4 0.26 0.25
5 2.78 2.98
6 0.79 0.98
7 2.75 2.71
8 1.82 1.98
9 0.41 0.37
10 1.52 1.44
11 -0.72 -0.97
12 2.68 2.10
13 1.86 1.94
a. See Figure 1.       b. Ref. 23.       c. With Eq. 3.
For binding of classical cannabinoids in transfected COS-7 cells the best 
equation obtained is:
       
     (4)
with R=0.99 and SD=0.27. The analysis of variance of Eq. 4 gives 
F(6,5)=33.46 (p<0.001), showing that this equation is statistically significant.
 Here, for example,                  is the orbital nucleophilic superdelocalizability 
of the second virtual MO at atom 4,               is the orbital electrophilic 
superdelocalizability of the second occupied MO at atom 8 and                   is 
the orbital electrophilic superdelocalizability of the third occupied MO at atom 
10. In Table 2 the calculated log K
i
  are displayed. 
Table 2. Experimental and calculated CB
1
 receptor affinities of classical 
cannabinoids in transfected COS-7 cells.
Moleculea Experimental log Kb  (nM) Calculated log Kc (nM)
1 2.32 2.43
2 0.30 -0.12
3 1.58 1.61
4 -1.0 -0.67
6 0.79 0.84
7 1.70 1.64
8 1.90 1.99
9 -0.62 -0.73
10 1.41 1.28
11 -1.0 -0.85
12 1.51 1.53
13 1.51 1.43
a. Figure 1.        b. Ref. 23.       c. With Eq. 4.
For CB
1 
binding of indole-derived cannabinoids to rat brain P
2
  membranes 
no statistically significant equation was obtained for the original common 
skeleton variables. Upon adding the atomic reactivity indices of the first four 
carbon atoms of the N alkyl chain (see Fig. 5; for chains shorter than four 
S N9 (Lumo)
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atoms we used dummy atoms carrying properties set to zero) the best equation 
obtained was:
                          
(5)
       
    
with R=0.96 and SD=0.31. The analysis of variance of Eq. 5 gives F(3,7)= 
24.97 (p<0.001), showing that this equation is statistically significant. Here,  
O
N
 is the orientational effect of the N-substituent (atom 7 of Fig. 6), Q
C3
 is the 
net charge of the third carbon atom of the N-alkyl substituent, and        
is the total atomic nucleophilic superdelocalizability of the fourth carbon atom 
of the N-substituent. The predicted  values are shown in Table 3. The results 
of Student’s t-test are: t[Q
C3
]= 1.80 (p≅ 0.1), t[        ]= -8.13 (p< 0.0001) 
and t[O
N
]= 3.06 (p< 0.02). The squares of the internal correlation coefficients 
are:                           = -0.68, 
Table 3. Experimental and calculated CB
1
 binding of indole-derived 
cannabinoids to rat brain P
2
 membranes.
Moleculea Experimental log Kb (nM) Calculatedlog Kc (nM)
1 3.07 3.12
2 2.21 2.59
3 1.34 1.06
4 0.98 1.09
5 1.68 1.31
6 3.14 3.12
7 3.02 2.59
8 0.95 1.05
9 0.95 1.09
10 0.99 1.30
11 2.11 2.01
a. Figure 2.       b. Ref. 24.      c. With Eq. 5.
For the inhibition of [3H]-WIN-55212-2 binding to rat cerebellar membranes 
by aminoalkylindole-derived cannabinoids the best equation obtained is: 
                                                                                                                                
(6)
with n=14, R=0.85, SD=0.25 and F(5,8)= 4.58 (p<0.05). Here, for example, 
D
1
(HOMO) is the orbital electronic density of the HOMO MO at atom 1, and
is the total atomic electrophilic superdelocalizability of atom 14. Table 4 
shows the predicted log K
i
 values.
Table 4. Experimental and calculated  inhibition of  binding to rat 
cerebellum membranes by aminoalkylindole derived cannabinoids.
Moleculea
Experimental
logKb (nM)
Calculated logKb
(nM)
1 2.37 2.43
2 2.97 2.93
3 2.74 2.67
4 2.65 2.73
5 2.63 2.73
6 2.22 2.18
7 2.06 2.03
8 2.25 2.05
9 2.72 2.41
10 2.59 2.60
11 1.95 2.40
12 2.52 2.38
13 2.04 1.95
14 1.61 1.96
a. See Fig. 3.    b. Ref. 25.     c. With Eq. 6.
For the CB
2 
binding of classical cannabinoids in transfected COS-7 cells 
the best equation obtained is:
 
(7)
with n=12, R=0.99, SD=0.23 and F(5,7)=44.88 (p<0.001). Here 0
1
 and  0
3
 
are, respectively, the orientational effects of the substituents attached to atom 
6 and to atom 10 of the common skeleton (see Fig. 6). Table 5 shows the 
predicted .
Figure 6. Common skeleton numbering for aminoethylindole-derived 
cannabinoids.
Table 5. Experimental and calculated CB
2
 receptor affinities of classical 
cannabinoids.
Moleculea
Experimental
logKb (nM)
Calculated logKb
(nM)
1 2.10 1.94
2 0.18 0.03
3 1.42 1.42
4 -0.70 -0.49
6 0.68 0.76
7 1.24 1.16
8 1.51 1.64
9 -0.70 -0.47
10 0.87 0.81
11 -0.77 -1.14
12 2.23 2.17
13 1.24 1.13
a. See Fig. 1    b. Ref. 23    c. Eq. 7.
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DISCUSSION
We shall make first some evolutionary considerations. Genes encoding 
orthologues of the mammalian CB
1
 receptor have been identified in a fish, an 
amphibian and a bird, indicating that CB
1
 receptors may occur throughout the 
vertebrates33. The zebra finch CB
1
 receptor is highly expressed in brain with an 
amino acid sequence 92% identical to that of the human CB
1
 receptor34. The 
rat CB
1
 receptor shares 97.3% sequence identity with the human CB
1
 receptor, 
with 100% identity within the transmembrane regions35.
On the other hand, human and rat cannabinoid CB
2
 receptors only share 
81% amino acid identity36. Also, a gene that encodes an ortholog of mammalian  
receptors CB
2 
was detected in the tropical puffer fish (“Fugu rubripes”)37. 
All this indicates that the gene duplication event that gave rise to CB
2
 and 
CB
2
 receptors occurred before the divergence of teleosts and tetrapods (350 
million years ago).
Finally, the human cannabinoid receptors share only 44% amino acid 
identity overall (which rises to 68% shared identity in the transmembrane 
domains), yet most ligands do not discriminate between receptor subtypes38.
Therefore our  QSAR results, obtained from experiments with the rat 
receptor (for CB
1
 receptors African green monkey kidney cells transfected with 
rat CB
1
 cDNA, rat brain synaptosomal membrane preparations, rat cerebellar 
membranes and rat brain P
2
 membranes were used) can be applied to humans 
if and only if the amino acid sequence and 3D structure of the receptor site at 
which our molecules bind is conserved in humans and rats..
Our results indicate that the variation of the various receptor affinities 
analyzed here are related to the variation of a definite set of molecular reactivity 
indices. We must note that our results concern only in vitro affinities and that 
nothing can be said about the in vivo pharmacological effects of the compounds 
studied here. We shall carry out the discussion of the statistical equations by 
dividing the indices appearing in the equations into two groups. In the first one, 
we place those indices for which p(Student) ≤ 0.001 and in the second one the 
indices for which p(Student) > 0.001. Note that the choice of t is arbitrary. 
Let us remember that the results of the Student’s test are associated with the 
significance of the individual variables appearing in the different regression 
equations. The squares of the internal correlation coefficients indicate the 
percentage of correlation between two given variables.
 As the interaction pharmacophore is defined by the atoms and/or group of 
atoms having the local electronic indices whose variation explains the variation 
of the affinity constants, analysis of the statistical equations will give a first 
insight as to its structure. If one or more atoms and/or group of atoms have 
a constant value for some reactivity indices, they will not appear accounting 
for the variation of the biological property and will not appear in the structure 
of the interaction pharmacophore. This is the main reason to carry out QSAR 
studies for different molecular families in which the position and the nature of 
the substituents vary.
The CB
1
 binding results analyzed here were obtained using tissues 
containing only CB
1
 receptors. Therefore, we expect the study of the resulting 
equations to provide some clue features about the cannabinoid-CB
1
 receptor 
interaction. Nevertheless, we must stress that it is not known if the CB
1
 
receptors have exactly the same conformation and local atomic environment in 
all these biological preparations.
The analysis of Eq. 3 (Table 1 and the Supplementary Material) shows that 
the most relevant variables describing the binding of classical cannabinoids 
to CB
1
 receptors are a high electron density on atom 10 at the level of the 
third occupied MO (SHOMO), a high electron accepting capacity of atom 9 
at the LUMO level, and a large orientational effect of the substituent attached 
to atom 10 (O
3
, see Fig. 4). This suggests that the cannabinoid- CB
1 
receptor 
binding is mainly orbital and sterically-controlled39. As atoms 9 and 10 bonded 
to each other, we may think that they interact with a receptor counterpart 
composed of two bonded atoms. They can be, for example, a backbone C=O 
group  in which one atom acts as an electron donor and the other as an electron 
acceptor. The requirement of a high value for O
3
 indicates that the cannabinoid 
molecule needs time and a proper orientation to match the receptor electrostatic 
potential. The next statistically relevant variables are the net charge of atom 5, 
that should be positive, and the orientational effect of the substituent attached 
to atom 12 (O
2
). A small value for  suggests that this orientational effect could 
modulate the effect of O
3
. The least statistically significant variable is the net 
charge of atom 9 that should be positive to be in physical agreement with the 
abovementioned electron accepting capacity of atom 9.
The analysis of Eq. 4 (see Table 4 and the Supplementary Material) shows 
that CB
1
 binding in transfected COS-7 cells is associated with a high electron 
accepting capacity of atom 7 at the NLUMO level and a low electron donating 
capacity of atom 8 at the NHOMO level. The interaction appears to be mainly 
orbital-controlled. Interestingly, as in the case of Eq. 3 again we find two 
bonded atoms participating in the CB
1
-ligand interaction. The next statistically 
relevant variable is a low electron-donating capacity of atom 10 at the SHOMO 
level. This is not contradictory with the requirement of a high electron density 
in atom 10 at the level of the same MO in Eq. 3. This is so when a high electron 
density over the atom is associated with a SHOMO energy lying sufficiently 
below the HOMO.
Before suggesting a putative structure for the CB
1
 pharmacophore we 
would like to make some comments. Given the almost 100% homology of 
human and rat receptors, the results reported here for rats should be useful for 
humans. It has been shown that an amino acid located  on the extracellular 
half of the third transmembrane domain of the human CB
1
 receptor, Lys192 , is 
essential for the binding of anandamide, CP-55940 and HU-210; but not for 
the binding of WIN-55212-2 (see Fig. 7). This fact suggests that WlN-55212-
2 must interact with the cannabinoid receptor through at least one point of 
interaction that is distinct from those of the three other agonists40. Moreover, 
when Lys is mutated to an Ala, HU-210, CP-55940, and anandamide failed to 
compete for [3H]-WIN-55212-2 binding to the mutant cannabinoid receptor40. 
This indicates that the charged amine residue is necessary for cannabinoid 
binding. We suggest that Lys could interact with O16 of Fig. 4 through a 
hydrogen bond because lysines are often found buried with only the amino 
group exposed to solvent. 
Figure 7. CP-55940, HU-210 and WIN-55212-2.
On the other hand, it has been suggested from molecular dynamics 
simulations that a ligand conformational change in CP-55244 (see Fig. 8), 
induced by rotating around a couple of dihedral angles, allows the C10 side 
chain (see Fig. 4) to trigger a CB
1
 receptor conformational change. This 
conformational change could be a major driving force leading to G-protein 
activation41. We are of the opinion that such a conclusion is a loose one. To 
support this hypothesis a study should be carried out at least with some classical 
cannabinoids carrying a pentyl chain at C10 and with anandamide. As we have 
shown above, the C10 side chain orientational parameter contribution should be 
high for a better affinity. This is achieved with the most extended conformation. 
Besides, given the high selectivity of cannabinoid receptors achieved through 
several hundred of million years, it is doubtful that a simple conformational 
change of the dimethylheptyl chain (DMH) should be responsible for such an 
important chain of events.
The high number of variables related to ring C appearing in Eq. 3 and 4 
strongly suggests that this ring must be fully aromatic.  On the other hand, 
we must consider that ring A in Fig. 4 does not need to be fully aromatic, as 
is shown by the affinities of molecules 8-12 of Fig. 1 and Table 1. Moreover, 
molecules such as CP-55940 and CP-55244 present an equivalent fully 
saturated A ring. Thus, π electrons on this ring are not needed for interaction 
with CB
1
  receptors.
J. Chil. Chem. Soc., 53, Nº 1 (2008)
1398
Figure 8. CP-55244, anandamide and a proposed molecular system.
Figure 9 displays a proposal of a CB
1
  pharmacophore encompassing the 
main results of Eq. 3 and 4 and the above comments.
Equation 5 is a very interesting case. No statistically significant equation 
was obtained by using atomic reactivity indices for the common skeleton 
depicted in Fig. 2. This surely indicates that all the variables belonging to this 
skeleton which participate in the ligand-CB
1
 receptor interaction are constant. 
Equation 5 (see Table 3) only allows us to suggest that the N-alkyl chains 
could participate in the interaction with the receptor through dispersion forces 
and through their conformational state at the interaction time. In any case, as 
Eq. 5 shows, these effects are very small. However, we can make the following 
considerations. The first one is that in this family only the carbonyl oxygen 
could H bond to Lys. If this is so, then the pyrrole ring (C in Fig. 5) and the N-
alkyl chain are equivalent, respectively, to ring C and to the n-pentyl chain at 
C10 of classical cannabinoids. As to this date we have not been able to include 
formally dispersion forces and static polarizabilities in our QSAR model, we 
think that Q
C3
  and           approximate a representation of these effects. This 
effect was included in Fig. 9 under “dispersion forces” close to the DMH chain. 
More experimental and theoretical work is needed to solve this interesting 
problem.
least one point of interaction that is distinct from those of other agonists. Now, 
if we examine equations 5 and 6 and their corresponding skeletons (Figs. 5 and 
6) we find that it is possible to make a correspondence between          of Eq. 5 and    
of Eq. 6. For these reasons we suggest that the ethylmorpholine fragment is 
equivalent to the DMH side chain of classical cannabinoids and that oxygen 
25 (the morpholine oxygen) is the atom through which WIN-55212-2 binds 
to the site that is not available to classical cannabinoids and anandamide. This 
second site, then, is located not far from the DMH chain and interacts through a 
H bond. If this is correct, then the proposed molecular system depicted in Fig. 8 
should display a binding profile similar to that of classical cannabinoids. After 
the above orientation and alignment rules have been defined as a basis for the 
comparison of noncongeneric molecules, it should be possible to associate the 
localization of molecular fragments of these systems with known molecular 
systems such as classical cannabinoids. These associations are depicted in Fig. 
10. This seems to be more than a coincidence because our preliminary QSAR 
results for the interaction of arachidonic acid derivatives with cannabinoid 
receptors indicate that the net charges of the carbon chain are statistically 
relevant variables (Gómez-Jeria et al., unpublished results). 
Figure 9. Proposed pharmacophore for classical cannabinoids interacting 
with CB
1
  receptors.
The analysis of Eq. 6 (see Table 4 and the Supplementary Material) shows 
that the variation of the receptor affinity appears to be mainly orbital-controlled, 
but we must note that equation 6 is statistically poor. This is explained by the 
fact that the experimental set of values selected for the regression analysis only 
covers a small range of values. Therefore, regression analysis is trying to explain 
small variations in affinity that can be part of the experimental error. There is 
another very interesting and puzzling fact that we shall comment on. First, we 
must notice that this molecular family is structurally similar to WIN-55212-2 
(Fig. 7). Second, WIN-55212-2 binds to the cannabinoid receptor through at 
Figure 10. Proposed structural relationships between indole-derived 
cannabinoids, aminoalkylindoles and classical cannabinoids.
The variation of the affinity of classical cannabinoids for CB
2
  receptors in 
transfected COS-7 cells is shown in Eq. 7. The interaction is mainly controlled 
by a large orientational effect of the substituent attached to atom 10 (O
3
, see 
Fig. 4) and a good electron accepting capacity of atom 10 at the LUMO level. 
The high value for the O
3
  orientational effect seems to be common to CB
1
  
(see Eq. 3) and CB
2
  receptors. A long time ago the increase in pharmacological 
activity associated with the replacement of the pentyl group at position 10 in 
Fig 4 by a 1,1-dimethylheptyl substituent was noted42. We may hypothesize 
that, if the O
3
  orientational effect is really a statistically relevant variable for 
both cannabinoid receptors, then it is a property that has been conserved for 
about 400 million years. 
The appearance of  is compatible with a low electron-donating 
capacity of atom 10 at the SHOMO level as discussed earlier. The next 
relevant variables are a high value for the orientational effect of the substituent 
attached to atom 6 (O
1
, see Fig. 4), a positive net charge on atom 12 and a 
high electron density of the NHOMO on atom 16. O
1
  does not appear in CB
1
-
related equations. If this property helps to differentiate ligand binding to both 
cannabinoid receptors it should be a phylogenetically newer CB
2
  characteristic. 
A positive net charge on atom 12 is consistent with an O atom bonded to it. A 
high value for the electronic density of the NHOMO of atom 16 is indicative 
of the participation of the oxygen atom as an electron donor, maybe through 
a H bond.
Interestingly, and contrary to the case of CB
1
  receptors, when the lysine 
residue of the extracellular half of the third transmembrane domain of the 
human CB
2
  receptor is mutated to an alanine residue, the receptor’s ability 
to recognize anandamide, WIN-55212-2, CP-55940, cannabinol and -THC 
is maintained. Only when the serine residue, unique to the CB
2
  receptor, was 
mutated to glycine in the alanine mutant, this double mutant retains the ability 
to bind aminoalkylindoles but loses affinity for classical cannabinoids43. These 
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results could indicate that, in CB
2
  receptors, the lysine residue lost its H-bonding 
function being replaced by a serine residue, probably at a close location. Also, 
it seems that aminoalkylindoles bind to a second site that is not available to 
classical cannabinoids as in the case of CB
1
  receptors. These differences in the 
mode of binding of cannabinoids to CB
1
  and CB
2
  receptors are also clearly 
shown by the QSAR results for cannabinoid-mediated inhibition of adenylyl 
cyclase32.
CONCLUSIONS
We have shown, starting from a model-based method44, that the in vitro 
binding of classical cannabinoids to CB
1
  and CB
2
  receptors seems to be 
regulated by different mechanisms. In indole-derived cannabinoids the pyrrole 
ring and the N-alkyl chain are equivalent, respectively, to aromatic ring C and 
to the n-pentyl chain of classical cannabinoids. In aminoalkylindole-derived 
cannabinoids the ethylmorpholine fragment is equivalent to the pentyl side 
chain of classical cannabinoids. In aminoalkylindole-derived cannabinoids the 
morpholine oxygen is the atom through which WIN-55212-2 and analogous 
molecules bind to the site that is not available to classical cannabinoids and 
anandamide.
Supplementary Material. A pdf file containing all the statistical results 
for each QSAR equation is available.
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